Oxford Biomedica (OTCMKTS:OXBDF) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.
A number of other research analysts have also weighed in on OXBDF. HC Wainwright reissued a “buy” rating on shares of Oxford Biomedica in a research note on Tuesday, October 31st. Zacks Investment Research lowered shares of Oxford Biomedica from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st.
Oxford Biomedica (OTCMKTS OXBDF) opened at $0.11 on Wednesday. Oxford Biomedica has a 12 month low of $0.04 and a 12 month high of $0.16.
COPYRIGHT VIOLATION NOTICE: “Oxford Biomedica (OXBDF) Stock Rating Lowered by ValuEngine” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/03/oxford-biomedica-oxbdf-stock-rating-lowered-by-valuengine.html.
Oxford Biomedica Company Profile
Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.